Safety and efficacy of immune checkpoint inhibitors as a bridge to allogeneic hematopoietic stem cell transplantation in classical Hodgkin lymphoma: A systematic review and meta-analysis.
Pragya Jain, Jacob Thompson, Viraj Panchal et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the safety and efficacy of immune checkpoint inhibitors (ICIs) as a bridge to allogeneic hematopoietic stem cell transplantation (allo-HCT) in patients with classical Hodgkin lymphoma (cHL). Analyzing data from seven studies with 739 patients, the findings indicated favorable post-transplant survival outcomes and low non-relapse mortality rates, supporting the use of ICIs in this context.
Key findings
- Pooled overall survival rates post-transplant were high across timepoints.
- Non-relapse mortality rates remained consistently low through long-term follow-up.
- Acute graft-versus-host disease (GVHD) occurred at a meaningful frequency, with severe cases in a smaller subset.
- Chronic GVHD was observed in approximately one-quarter of patients at follow-up.
Why it matters
The findings highlight the potential of ICIs to improve survival and disease control in cHL patients undergoing allo-HCT, addressing concerns about post-transplant complications and safety profiles. This information is crucial for clinicians considering treatment strategies for relapsed or refractory cHL.